{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:14:55Z","timestamp":1781878495972,"version":"3.54.5"},"reference-count":15,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMP15-00025 and PI18-01374"],"award-info":[{"award-number":["PMP15-00025 and PI18-01374"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2020,10,20]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Recessive mutations in the thymidine\nkinase 2 (<jats:italic>TK2)<\/jats:italic> gene cause a rare mitochondrial myopathy, frequently with severe respiratory involvement. Deoxynucleoside therapy is currently under investigation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Research question<\/jats:title>\n                  <jats:p>What is the impact of nucleosides in respiratory function in patients with TK2-deficient myopathy?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study design and methods<\/jats:title>\n                  <jats:p>Retrospective observational study of patients treated with deoxycytidine and deoxythymidine. Evaluations were performed every 3 to 4 months after treatment during approximately 30 months. Forced vital capacity (FVC), maximuminspiratory and expiratory pressures (MIP\/MEP), sniff nasal inspiratory pressure (SNIP), cough peak flow (CPF), arterial blood gas and nocturnal pulse oximeter (SpO2) were collected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We studied six patients, five of which were women, with a median age at onset of symptoms was 35.8 (range 5 to 60) years old. Patients presented a restrictive ventilatory pattern (median FVC of 50 (26 to 71)%) and severe neuromuscular respiratory weakness (MIP 38 (12 to 47)% and SNIP 14 (8 to 19) cmH2O). Four patients required ventilatory support before starting the treatment. FVC improved by 6%, proportion of sleep time with SpO2 &lt;90% diminished from 14% to 0%, CPF increased by 23%, MEP increased by 73%, production and management of bronchial secretions improved and respiratory infections diminished.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interpretation<\/jats:title>\n                  <jats:p>Early detection of respiratory involvement requires an active search, even in asymptomatic patients. The nucleosides therapy may improve respiratory function, and stabilise the loss of respiratory capacity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2020-000774","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T15:30:10Z","timestamp":1606491010000},"page":"e000774","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Deoxynucleoside therapy for respiratory involvement in adult patients with thymidine kinase 2-deficient myopathy"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct03845712","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ana","family":"Hernandez-Voth","sequence":"first","affiliation":[{"name":"Servicio de Neumolog\u00eda, Unidad de Ventilaci\u00f3n Mec\u00e1nica, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Servicio de Neurologia, Unidad de Enfermedades Neuromusculares, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Sayas Catalan","sequence":"additional","affiliation":[{"name":"Servicio de Neumolog\u00eda, Unidad de Ventilaci\u00f3n Mec\u00e1nica, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Servicio de Neurologia, Unidad de Enfermedades Neuromusculares, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Instituto de Investigacion imas12, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Corral Blanco","sequence":"additional","affiliation":[{"name":"Servicio de Neumolog\u00eda, Unidad de Ventilaci\u00f3n Mec\u00e1nica, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Servicio de Neurologia, Unidad de Enfermedades Neuromusculares, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Casta\u00f1o Mendez","sequence":"additional","affiliation":[{"name":"Servicio de Neumolog\u00eda, Unidad de Ventilaci\u00f3n Mec\u00e1nica, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Martin","sequence":"additional","affiliation":[{"name":"Instituto de Investigacion imas12, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Departamento de Bioqu\u00edmica, Laboratorio de Enfermedades Mitocondriales, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"De Fuenmayor Fernandez de la Hoz","sequence":"additional","affiliation":[{"name":"Servicio de Neurologia, Unidad de Enfermedades Neuromusculares, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Villena Garrido","sequence":"additional","affiliation":[{"name":"Instituto de Investigacion imas12, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Servicio de Neumolog\u00eda, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Dominguez-Gonzalez","sequence":"additional","affiliation":[{"name":"Servicio de Neurologia, Unidad de Enfermedades Neuromusculares, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Instituto de Investigacion imas12, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"2025083112365098000_7.1.e000774.1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddr438"},{"key":"2025083112365098000_7.1.e000774.2","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2017-105012"},{"key":"2025083112365098000_7.1.e000774.3","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-019-1071-z","article-title":"Late-Onset thymidine kinase 2 deficiency: a review of 18 cases","volume":"14","author":"Dom\u00ednguez-Gonz\u00e1lez","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2025083112365098000_7.1.e000774.4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ymgme.2018.04.012","article-title":"Clinical and molecular spectrum of thymidine kinase 2-related mtDNA maintenance defect","volume":"124","author":"Wang","year":"2018","journal-title":"Mol Genet Metab"},{"key":"2025083112365098000_7.1.e000774.5","doi-asserted-by":"publisher","DOI":"10.1136\/thx.35.8.603"},{"key":"2025083112365098000_7.1.e000774.6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nmd.2015.11.009","article-title":"Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator use in late-onset Pompe disease","volume":"26","author":"Johnson","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"2025083112365098000_7.1.e000774.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200403-314OC"},{"key":"2025083112365098000_7.1.e000774.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2005.01351.x"},{"key":"2025083112365098000_7.1.e000774.9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24922"},{"key":"2025083112365098000_7.1.e000774.10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ebiom.2019.07.037","article-title":"Bioavailability and cytosolic kinases modulate response to deoxynucleoside therapy in TK2 deficiency","volume":"46","author":"Lopez-Gomez","year":"2019","journal-title":"EBioMedicine"},{"key":"2025083112365098000_7.1.e000774.11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ebiom.2019.07.042","article-title":"Age-Related metabolic changes limit efficacy of deoxynucleoside-based therapy in thymidine kinase 2-deficient mice","volume":"46","author":"Bl\u00e1zquez-Bermejo","year":"2019","journal-title":"EBioMedicine"},{"key":"2025083112365098000_7.1.e000774.12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ana.25506","article-title":"Deoxynucleoside therapy for thymidine kinase 2-deficient myopathy","volume":"86","author":"Dom\u00ednguez-Gonz\u00e1lez","year":"2019","journal-title":"Ann Neurol"},{"key":"2025083112365098000_7.1.e000774.13","first-page":"513","article-title":"Office spirometry for lung health assessment in adults: a consensus statement from the National lung health education program","volume":"45","author":"Ferguson","year":"2000","journal-title":"Respir Care"},{"key":"2025083112365098000_7.1.e000774.14","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.arbres.2012.12.003","article-title":"Guidelines for the management of respiratory complications in patients with neuromuscular disease. Sociedad Espa\u00f1ola de Neumolog\u00eda Y Cirug\u00eda Tor\u00e1cica (SEPAR)","volume":"49","author":"Farrero","year":"2013","journal-title":"Arch Bronconeumol"},{"key":"2025083112365098000_7.1.e000774.15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/resp.13525","article-title":"NIV in amyotrophic lateral sclerosis: The 'when' and 'how' of the matter","volume":"24","author":"Morelot-Panzini","year":"2019","journal-title":"Respirology"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2020-000774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T19:37:00Z","timestamp":1756669020000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2020-000774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,11,27]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/bmjresp-2020-000774"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2020-000774","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}